Quick Dispatch:
Your weight regain and cardiometabolic effects after withdrawal of semaglutide Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your weight regain and cardiometabolic effects after withdrawal of semaglutide Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine ships.
Need Help?
Questions about weight regain and cardiometabolic effects after withdrawal of semaglutide Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for weight regain and cardiometabolic effects after withdrawal of semaglutide Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine in your area.
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP‐1 Receptor Agonists - Shah - 2026 - Diabetes, Obesity and Metabolism
26.58
Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials: Cell Reports Medicine
22.45
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
29.04
Exploring beyond numeric weight loss: The metabolic effects of semaglutide
28.01
Weight gain after stopping GLP-1 drugs (by Patricia Toro, MD MPH)
22.30
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
23.49
Weight regain after the withdrawal of tirzepatide (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity
21.04
